Renal complications of immune checkpoint blockade

Curr Probl Cancer. Mar-Apr 2017;41(2):100-110. doi: 10.1016/j.currproblcancer.2016.12.004. Epub 2016 Dec 19.

Abstract

Immune checkpoint inhibitors have been approved for a variety of cancer species. Renal complications in use of these agents are not very common compared with other immune-related adverse events (irAE). However, it is crucial for physicians to recognize and manage renal manifestations of irAE. In this review, we will summarize the up-to-date knowledge of the clinical presentation, pathologic features, and management of renal irAE. In addition, we will discuss the safety of immune checkpoint inhibitors in patients with chronic kidney disease as well as in kidney transplant recipients.

Keywords: CTLA-4; Immune check point inhibitor; PD-1; acute kidney injury; chronic kidney injury; transplant.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Humans
  • Immunomodulation / drug effects*
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / immunology*
  • Kidney Diseases / prevention & control
  • Neoplasms / complications*
  • Neoplasms / drug therapy

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents